No indication of carcinogenicity or impairment of fertility/fetal viability FDA Label.
Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients L852. Velpatasvir acts as a defective substrate for NS5A (Non-Structural Protein 5A), a non-enzymatic viral protein that plays a key role in Hepatitis C Virus replication, assembly, and modulation of host immune responses A19175. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as velpatasvir. Notably, velpatasvir has a significantly higher barrier to resistance than the first generation NS5A inhibitors, such as DB09027 and DB09102, making it a highly potent and reliable alternative for treatment of chronic Hepatitis C A19637.
In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Velpatasvir as first line therapy in combination with sofosbuvir for all six genotypes of Hepatitis C L852. Velpatasvir is currently only available within a fixed dose combination product as Epclusa with DB08934, another direct acting antiviral. Goals of therapy for Epclusa include the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality and risk of requiring a liver transplant A19626.
Since June 2016, Velpatasvir has been available as a fixed dose combination product with DB08934, as the commercially available product Epclusa. Epclusa is the first combination HCV product indicated for the treatment of all genotypes of Hepatitis C with or without cirrhosis. It is also currently the most potent HCV antiviral medication on the market with a sustained virologic response (SVR) after 12 weeks of therapy of 93-99% depending on genotype and level of cirrhosis and a high barrier to resistance L852. Both Canadian and American guidelines list Epclusa as a first line recommendation for all genotypes of HCV L852, A19626.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Afatinib | The serum concentration of Afatinib can be increased when it is combined with Velpatasvir. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Velpatasvir. |
| Brentuximab vedotin | The serum concentration of Brentuximab vedotin can be increased when it is combined with Velpatasvir. |
| Colchicine | The serum concentration of Colchicine can be increased when it is combined with Velpatasvir. |
| Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Velpatasvir. |
| Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Velpatasvir. |
| Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Velpatasvir. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Velpatasvir. |
| Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Velpatasvir. |
| Ranolazine | The serum concentration of Ranolazine can be increased when it is combined with Velpatasvir. |
| Silodosin | The excretion of Silodosin can be decreased when combined with Velpatasvir. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Velpatasvir. |
| Everolimus | The serum concentration of Everolimus can be increased when it is combined with Velpatasvir. |
| Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Velpatasvir. |
| Mifepristone | The serum concentration of Velpatasvir can be increased when it is combined with Mifepristone. |
| Eluxadoline | The serum concentration of Eluxadoline can be increased when it is combined with Velpatasvir. |
| Vincristine | The excretion of Vincristine can be decreased when combined with Velpatasvir. |
| Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Velpatasvir. |
| Lumacaftor | The serum concentration of Velpatasvir can be decreased when it is combined with Lumacaftor. |
| Secobarbital | The metabolism of Velpatasvir can be increased when combined with Secobarbital. |
| Rifampin | The metabolism of Velpatasvir can be increased when combined with Rifampicin. |
| Phenobarbital | The metabolism of Velpatasvir can be increased when combined with Phenobarbital. |
| Bexarotene | The metabolism of Velpatasvir can be decreased when combined with Bexarotene. |
| Diltiazem | The metabolism of Velpatasvir can be decreased when combined with Diltiazem. |
| Medroxyprogesterone acetate | The metabolism of Velpatasvir can be decreased when combined with Medroxyprogesterone acetate. |
| Nicardipine | The metabolism of Velpatasvir can be decreased when combined with Nicardipine. |
| Irbesartan | The metabolism of Velpatasvir can be decreased when combined with Irbesartan. |
| Oxybutynin | The metabolism of Velpatasvir can be decreased when combined with Oxybutynin. |
| Fluvastatin | The metabolism of Velpatasvir can be decreased when combined with Fluvastatin. |
| Pioglitazone | The metabolism of Velpatasvir can be decreased when combined with Pioglitazone. |
| Abiraterone | The metabolism of Velpatasvir can be decreased when combined with Abiraterone. |
| Levothyroxine | The metabolism of Velpatasvir can be decreased when combined with Levothyroxine. |
| Loratadine | The metabolism of Velpatasvir can be decreased when combined with Loratadine. |
| Trimethoprim | The metabolism of Velpatasvir can be decreased when combined with Trimethoprim. |
| Fluticasone propionate | The metabolism of Velpatasvir can be decreased when combined with Fluticasone propionate. |
| Clopidogrel | The metabolism of Velpatasvir can be decreased when combined with Clopidogrel. |
| Candesartan cilexetil | The metabolism of Velpatasvir can be decreased when combined with Candesartan cilexetil. |
| Salmeterol | The metabolism of Velpatasvir can be decreased when combined with Salmeterol. |
| Gemfibrozil | The metabolism of Velpatasvir can be decreased when combined with Gemfibrozil. |
| Fluticasone | The metabolism of Velpatasvir can be decreased when combined with Fluticasone. |
| Mometasone furoate | The metabolism of Velpatasvir can be decreased when combined with Mometasone furoate. |
| Felodipine | The metabolism of Velpatasvir can be decreased when combined with Felodipine. |
| Betrixaban | The serum concentration of Betrixaban can be increased when it is combined with Velpatasvir. |
| Vemurafenib | The serum concentration of Velpatasvir can be increased when it is combined with Vemurafenib. |
| Apalutamide | The serum concentration of Velpatasvir can be decreased when it is combined with Apalutamide. |
| Pitolisant | The serum concentration of Velpatasvir can be decreased when it is combined with Pitolisant. |
| Isavuconazole | The serum concentration of Velpatasvir can be increased when it is combined with Isavuconazole. |
| Isavuconazonium | The serum concentration of Velpatasvir can be increased when it is combined with Isavuconazonium. |
| Imatinib | Imatinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Sulfasalazine | Sulfasalazine may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Novobiocin | Novobiocin may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Hesperetin | Hesperetin may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Rabeprazole | Rabeprazole may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Genistein | The metabolism of Velpatasvir can be decreased when combined with Genistein. |
| Topiroxostat | The metabolism of Velpatasvir can be decreased when combined with Topiroxostat. |
| Daidzin | Daidzin may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Fusidic acid | The metabolism of Velpatasvir can be decreased when combined with Fusidic acid. |
| Naringenin | Naringenin may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Vandetanib | Vandetanib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Eltrombopag | The metabolism of Velpatasvir can be decreased when combined with Eltrombopag. |
| Simeprevir | The metabolism of Velpatasvir can be decreased when combined with Simeprevir. |
| Safinamide | Safinamide may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Teriflunomide | The metabolism of Velpatasvir can be decreased when combined with Teriflunomide. |
| Cannabidiol | Cannabidiol may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Palbociclib | Palbociclib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Folic acid | Velpatasvir may decrease the excretion rate of Folic acid which could result in a higher serum level. |
| Allopurinol | Velpatasvir may decrease the excretion rate of Allopurinol which could result in a higher serum level. |
| Celecoxib | Velpatasvir may decrease the excretion rate of Celecoxib which could result in a higher serum level. |
| Oxaliplatin | Velpatasvir may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. |
| Methotrexate | Velpatasvir may decrease the excretion rate of Methotrexate which could result in a higher serum level. |
| Clofarabine | Velpatasvir may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
| Nitrofurantoin | Velpatasvir may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
| Riluzole | Velpatasvir may decrease the excretion rate of Riluzole which could result in a higher serum level. |
| Tegaserod | Velpatasvir may decrease the excretion rate of Tegaserod which could result in a higher serum level. |
| Leflunomide | Velpatasvir may decrease the excretion rate of Leflunomide which could result in a higher serum level. |
| Rosuvastatin | Velpatasvir may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. |
| Alvocidib | Velpatasvir may decrease the excretion rate of Alvocidib which could result in a higher serum level. |
| Riociguat | Velpatasvir may decrease the excretion rate of Riociguat which could result in a higher serum level. |
| Lenvatinib | Velpatasvir may decrease the excretion rate of Lenvatinib which could result in a higher serum level. |
| Fimasartan | Velpatasvir may decrease the excretion rate of Fimasartan which could result in a higher serum level. |
| Delafloxacin | Velpatasvir may decrease the excretion rate of Delafloxacin which could result in a higher serum level. |
| Glasdegib | Velpatasvir may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
| Fostamatinib | Fostamatinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Gilteritinib | Gilteritinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Nabiximols | Nabiximols may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Fedratinib | The serum concentration of Velpatasvir can be increased when it is combined with Fedratinib. |
| Caffeine | Caffeine may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Dronabinol | The metabolism of Velpatasvir can be decreased when combined with Dronabinol. |
| Tazemetostat | Velpatasvir may decrease the excretion rate of Tazemetostat which could result in a higher serum level. |
| Pantoprazole | Pantoprazole may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Gefitinib | Gefitinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Beclomethasone dipropionate | Beclomethasone dipropionate may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Progesterone | Progesterone may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Lansoprazole | Lansoprazole may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Estradiol | Estradiol may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Buprenorphine | Buprenorphine may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Telmisartan | Telmisartan may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Sunitinib | Sunitinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
| Quercetin | Quercetin may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |